Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] stock went on an upward path that rose over 1.45% on Monday, amounting to a one-week price decrease of less than -5.20%.
Over the last 12 months, TNXP stock dropped by -99.11%. The one-year Tonix Pharmaceuticals Holding Corp stock forecast points to a potential upside of 99.5. The average equity rating for TNXP stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $23.28 million, with 186.89 million shares outstanding and 186.89 million shares in the current float. Compared to the average trading volume of 32.60M shares, TNXP stock reached a trading volume of 8575813 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Tonix Pharmaceuticals Holding Corp [TNXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNXP shares is $26.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNXP stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Noble Capital Markets have made an estimate for Tonix Pharmaceuticals Holding Corp shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 18, 2022. The new note on the price target was released on April 18, 2019, representing the official price target for Tonix Pharmaceuticals Holding Corp stock. Previously, the target price had yet another raise to $6, while ROTH Capital analysts kept a Buy rating on TNXP stock.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp is set at 0.02, with the Price to Sales ratio for TNXP stock in the period of the last 12 months amounting to 2.06. The Price to Book ratio for the last quarter was 0.28, with the Price to Cash per share for the same quarter was set at 0.16.
TNXP Stock Performance Analysis:
Tonix Pharmaceuticals Holding Corp [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.20. With this latest performance, TNXP shares dropped by -26.11% in over the last four-week period, additionally sinking by -97.81% over the last 6 months – not to mention a drop of -99.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TNXP stock in for the last two-week period is set at 37.27, with the RSI for the last a single of trading hit 34.76, and the three-weeks RSI is set at 34.44 for Tonix Pharmaceuticals Holding Corp [TNXP]. The present Moving Average for the last 50 days of trading for this stock 0.1486, while it was recorded at 0.1381 for the last single week of trading, and 3.6891 for the last 200 days.
Insight into Tonix Pharmaceuticals Holding Corp Fundamentals:
Tonix Pharmaceuticals Holding Corp’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.78 and a Current Ratio set at 3.33.
TNXP Stock EPS
With the latest financial reports released by the company, Tonix Pharmaceuticals Holding Corp posted 17.6/share EPS, while the average EPS was predicted by analysts to be reported at -44/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 61.6. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNXP.
Tonix Pharmaceuticals Holding Corp [TNXP] Institutonal Ownership Details
There are presently around $0.23%, or 0.23%% of TNXP stock, in the hands of institutional investors.
